COLUMBIA, Md., April 8, 2008 /PRNewswire/ -- Cylex(TM) has announced the appointment of Brad L. Stewart as President of the Company. Cylex is a global life sciences company that develops and manufactures research and in vitro diagnostic products based on its patented technology to assay cell-mediated immunity (CMI).
(Photo: http://www.newscom.com/cgi-bin/prnh/20080408/NETU096 )
"A major priority for Cylex has been the recruitment of an experienced leader who could bring greater focus to the company and convert our extraordinary patented technology assets into profitable product opportunities," said Seth Rudnick, MD, General Partner in Canaan VII (a Canaan Partners fund), a major investor in Cylex, in announcing Mr. Stewart's appointment. "We believe Brad is the individual who brings us that skill set."
"I am delighted to have been given this opportunity to join Cylex and to focus first and foremost on ways to expand the awareness of our first marketed product, the ImmuKnow(R) assay, within and beyond the transplant community," says Mr. Stewart. "I have already had the chance to identify means to accelerate understanding of the value of this technology in specific therapeutic areas. We are also convinced that Cylex can rapidly expand ex-US use of ImmuKnow to support patient care in many other countries. This is an exciting challenge for me personally, and I will have the backing of a talented team of professionals at Cylex who, I know, are eager to work with me in achieving very specific goals."
Mr. Stewart brings extensive leadership experience in the life sciences industry -- with biotech, pharmaceutical, orphan drug, diagnostic and related healthcare companies. Among other accomplishments, he established a new US business for a European pharmaceutical company; drove the strategic restructuring of the North American business unit of a global pharmaceutical company; created an operational improvement business within a major diagnostics company; and developed and managed joint ventures, including a multi-million dollar joint-venture with one of the world's largest pharmaceutical companies.
At Cylex, he will have full responsibility for global commercial operations, corporate strategy and business development.
About Cylex(TM) Inc.
Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow(R) is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the US and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The Company is based in Columbia, MD.
CONTACT: Lynn Shepherd, +1-267-250-7376, lshepherd@voxmedica.com or Ketura
Lispi, +1-215-925-9901, klispi@voxmedica.com, both of Vox Medica for Cylex,
Inc.
